CHO cell line selection represents a painful bottleneck in biotherapeutic development, particularly for complex molecules like bispecifics. At BPI Europe Digital Week 2021, Renee Tobias discussed how the Opto™ CLD workflow on the Beacon® system can help through accelerating early CLD by integrating high throughput cell sorting, cloning, culture, productivity, growth, and product quality assays into a single, 5-day automated process.
Find out how Amgen is transforming their antibody discovery and clonal cell line processes with the Berkeley Lights Platform.
Learn how the Beacon system’s superior cloning technology, automated imaging capabilities, and in-process quality controls provide definitive evidence of monoclonality to support regulatory approvals.
Find out how Catalent Biologics is able to select significantly higher expressing clonal cell lines with the Opto CLD workflow.